After FDA Rejection, Lexicon’s Type 1 Diabetes Drug Hit With Another Regulatory Delay

An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases of diabetic ketoacidosis.